Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal



Page Path
HOME > Search
2 "Palliative care"
Article category
Publication year
Review article
Dignity therapy for effective palliative care: a literature review
Se-Ryun Park, Yu-Jung Cha
Kosin Med J. 2022;37(3):192-202.   Published online September 27, 2022
  • 350 View
  • 39 Download
Abstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Dignity therapy for terminally ill patients in end-of-life care helps improve their psychological and spiritual well-being. In this study, the effectiveness and feasibility of dignity therapy in terminally ill patients were analyzed by reviewing previous studies. The review’s findings show that dignity therapy alleviates psychological distress and improves patients' spiritual well-being and dignity. In addition, many patients and their families found emotional support in generativity documents created through dignity therapy. Finally, the possibility of applying dignity therapy to palliative care in Korea in the future was explored. The findings indicate the influence of Eastern culture on recognizing death in patients who receive dignity therapy. Thus, dignity therapy shows promise as a contribution to improving palliative care; however, additional studies are needed to implement effective dignity therapy in the Korean context.
Original article
The effects of ketamine on pain control in stage IV cancer patients receiving palliative care
Seonghoon Kim, Jihun Kang, Jongsoon Choi, Eunhee Kong
Kosin Med J. 2022;37(1):37-45.   Published online March 14, 2022
  • 1,195 View
  • 33 Download
  • 1 Citations
Abstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
We evaluated the effects of intravenous ketamine on cancer pain in stage IV cancer patients receiving palliative care.
In total, 253 stage IV cancer patients with cancer pain hospitalized at a single tertiary hospital palliative care unit were included. The ketamine group contained 112 patients receiving ketamine, and the control group comprised 141 non-ketamine users. To evaluate the odds ratios (ORs) for favorable pain control, optimal pain control, and opioid-sparing effect among ketamine users, we used multivariable logistic regression adjusted for age and objective prognosis score. Differences in the visual analog scale (VAS) score, oral morphine equivalents, inter-dose frequency, and inter-dose amount were compared between both groups at the time of ketamine introduction (T0), after 24 hours (T1), and after 48 hours (T2) using repeated-measures analysis of covariance.
The ketamine group was more likely to show favorable pain control (OR, 3.84; 95% confidence interval [CI], 1.76–8.37) and an optimal response (OR, 3.99; 95% CI, 1.73–9.22) than the control group. Compared to the control group, the ketamine group showed a higher VAS score at T0, but a more evident VAS score reduction at T1 and T2 (pint<0.001). The ketamine group was less likely than the control group to experience depressive mood (OR, 0.31; 95% CI, 0.10–0.92), but had a higher risk of delirium (OR, 2.06; 95% CI, 1.12–3.91).
Our findings suggest that ketamine can effectively reduce refractory cancer pain in stage IV cancer patients.


Citations to this article as recorded by  
  • Is ketamine useful for pain management in patients with stage IV cancer?
    Sung Eun Kim
    Kosin Medical Journal.2022; 37(1): 1.     CrossRef

KMJ : Kosin Medical Journal